| 1. |
Badakhsh M, Dastras M, Sarchahi Z, et al. Complementary and alternative medicine therapies and COVID-19: a systematic review. Rev Environ Health 2021; 36: 443-50.
DOI
PMID
|
| 2. |
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19). JAMA 2020; 324: 782.
DOI
PMID
|
| 3. |
Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the new york city area. JAMA 2020; 323: 2052-59.
DOI
PMID
|
| 4. |
Zhong L, Lam WC, Yang W, et al. Potential targets for treatment of coronavirus disease 2019 (COVID-19): a review of Qing-Fei-Pai-Du-Tang and its major herbs. Am J Chin Med 2020; 48: 1051-71.
DOI
URL
|
| 5. |
Zhang L, Zheng X, Bai X, et al. Association between use of Qingfei Paidu Tang and mortality in hospitalized patients with COVID-19: a national retrospective registry study. Phytomedicine 2021; 85: 153531.
DOI
URL
|
| 6. |
Chen J, Wang YK, Gao Y, et al. Protection against COVID-19 injury by qingfei paidu decoction via anti-viral, anti-inflammatory activity and metabolic programming. Biomed Pharmacother 2020; 129: 110281.
DOI
URL
|
| 7. |
Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of COVID-19: a systematic review and Meta-analysis. Sci Rep 2021; 11: 16144.
DOI
PMID
|
| 8. |
Huang C, Huang L, Wang Y, et al. 6-Month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397: 220-32.
DOI
PMID
|
| 9. |
Sterne J, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.
|
| 10. |
Lo CK, Mertz D, Loeb M. Newcastle-Ottawa scale: comparing reviewers' to authors' assessments. Bmc Med Res Methodol 2014; 14: 45.
DOI
PMID
|
| 11. |
Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative Meta-analysis. J Clin Epidemiol 2008; 61: 64-75.
DOI
PMID
|
| 12. |
Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many Meta-analyses. J Clin Epidemiol 2008; 61: 763-9.
DOI
PMID
|
| 13. |
Sun YN, Lü WL, Xiao Y, et al. Qingfei Paidu Decoction for treatment of mild/moderate COVID-19 in 295 cases: a multi-centered study. Zhong Yi Za Zhi 2021; 62: 599-603.
|
| 14. |
Shi N, Liu B, Liang N, et al. Association between early treatment with Qingfei Paidu decoction and favorable clinical outcomes in patients with COVID-19: a retrospective multicenter cohort study. Pharmacol Res 2020; 161: 105290.
DOI
URL
|
| 15. |
Chen H, Qi S, Shen J. One-Compound-Multi-Target: combination prospect of natural compounds with thrombolytic therapy in acute ischemic stroke. Curr Neuropharmacol 2017; 15: 134-56.
DOI
URL
|
| 16. |
Cui H, Liu T, Li P, et al. An intersectional study of LncRNAs and mRNAs reveals the potential therapeutic targets of buyang huanwu decoction in experimental intracerebral hemorrhage. Cell Physiol Biochem 2018; 46: 2173-86.
DOI
PMID
|
| 17. |
DU HZ, Hou XY, Miao YH, Huang BS, Liu DH. Traditional Chinese Medicine: an effective treatment for 2019 novel coronavirus pneumonia (NCP). Zhong Guo Tian Ran Yao Xue 2020; 18: 206-10.
|
)
